Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy

The lead author with clinical stage I malignant pleural mesothelioma, epithelioid type, highly programmed cell death ligand 1 (PD-L1) positive, and BAP1 negative, experienced a prompt and exceptionally favorable response to pembrolizumab monotherapy. After cessation of treatment due to immune-relate...

Descripción completa

Detalles Bibliográficos
Autores principales: Hearon, Bernard F., Redelman, Kyle N., Elhomsy, Georges C., Moore, Jr., Dennis F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772860/
https://www.ncbi.nlm.nih.gov/pubmed/33442373
http://dx.doi.org/10.1159/000512013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772860/
https://www.ncbi.nlm.nih.gov/pubmed/33442373
http://dx.doi.org/10.1159/000512013

Ejemplares similares